April 26, 2024

• 

[THE INVESTOR] As of Jan. 24 01:56 P.M., Samjin Pharmaceutical declined 2.61% from yesterday to 31,750 won (US$27.26). It fell 8.78% over the past month. Standard deviation for the one month period stood at 1.9%.

Compared with its industry competitors listed on KOSPI, the monthly earnings rate of Samjin Pharmaceutical was negative, and its volatility for the one month was lower than that of its peer group’s.

The monthly return-on-risk, indicating the return on investment with consideration for risk, was -4.6%. Compared with the rest of the KOSPI industry, the return-on-risk was lower than the industrial mean of 2.1%.

■ Earnings & Valuation

Earnings report for 3Q (July – Sept.) of 2016
Revenue: 611.1 T   Up 1.8% on-quarter, up 9.5% on-year
Operating income: 119.5 T   Up 10.4% on-quarter, up 17.6% on-year
Net income: 91.2 T   Up 9.6% on-quarter, up 25.1% on-year

Investor Groups (Over the past five trading days)
Institutions 21.13%, Foreigners 33.16%, Individuals 45.69%

*Other investor groups including corporations are considered as “individuals.”

By HeRo (hero@heraldcorp.com)

This article is produced by the algorithm developed by the artificial 
intelligence developer ThinkPool in collaboration with Herald Corp.